Status:
WITHDRAWN
Aprepitant PO vs Ondansetron IV for Prevention of Postoperative Nausea and Vomiting
Lead Sponsor:
Northwell Health
Conditions:
Postoperative Nausea and Vomiting
Eligibility:
MALE
15-25 years
Phase:
NA
Brief Summary
Postoperative nausea and vomiting (PONV) persists as one of the more common complications of surgery. Although rarely life-threatening, it is the postoperative outcome that is most unfavorable to pati...
Eligibility Criteria
Inclusion
- Patients aged 15-25 who have reached skeletal maturity and are scheduled for Le Fort 1 osteotomy as part of standard care.
- Capable of providing informed consent.
Exclusion
- Patients with hypersensitivity to medications contraindicated with aprepitant: pimozide, terfenadine, astemizole, cisapride.
- Patients with a known vomiting disorder
- Patients who have vomited for any reason within 24 hours prior to surgery.
- Patients who are pregnant or nursing.
- Patients who are unable to provide informed consent.
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00699894
Start Date
June 1 2008
End Date
September 1 2008
Last Update
August 12 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Long Island Jewish Medical Center/Schneider's Children Hospital
New Hyde Park, New York, United States, 11040